

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

24 Aug 2026

**Investigating the effect of modified specific carbohydrate diet on disease severity, fecal calprotectin level and disability caused by the disease in people with ulcerative colitis.**

### Protocol summary

#### Study aim

Effect of Modified Specific Carbohydrate Diet on Disease Severity, Fecal Calprotectin Level and Disease-Related Disability in People with Ulcerative Colitis

#### Design

A clinical trial of a parallel type in which sufficient information about the objectives of the study, the type of intervention and the duration of the study will be explained to the volunteers who have the inclusion criteria. Before the start of the intervention, people will be grouped and matched based on gender (female/male) and the type of drug used.

#### Settings and conduct

Patients are randomly selected from those who visit in the hospital clinic. The diet delivered to control and intervention group patients is monitored during 6 weeks. At the beginning and end of the study, the main outcome variables are measured and compared to determine the impact of the intervention.

#### Participants/Inclusion and exclusion criteria

Inclusion criteria 1) Age between 20 and 60 years old 2) Suffering from ulcerative colitis with mild to moderate severity. Criteria for not entering the study 1) Changing the type and dosage of the drug consumed during the last month 2) Having other intestinal diseases or inflammatory and kidney diseases and diabetes 3) pregnancy or breastfeeding 4) use of antibiotics, or a anti inflammatory or multivitamins supplements during the intervention and in the period of one month before the intervention 5) use of tobacco and drugs 6) history of hospitalization during The last three months

#### Intervention groups

The intervention group will receive food menus and essential recommendations of a specific modified carbohydrate diet to be followed for 6 weeks, and the patients of the control group will receive nutritional recommendations related to their disease to be followed

for a period of 6 weeks.

#### Main outcome variables

Measurement of disease severity indicators, fecal calprotectin level and disability caused by the disease

### General information

#### Reason for update

#### Acronym

#### IRCT registration information

IRCT registration number: **IRCT20170202032367N8**

Registration date: **2023-03-28, 1402/01/08**

Registration timing: **prospective**

Last update: **2023-03-28, 1402/01/08**

Update count: **0**

#### Registration date

2023-03-28, 1402/01/08

#### Registrant information

##### Name

Hossien Imani

##### Name of organization / entity

Tehran University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8895 5975

##### Email address

h-imani@sina.tums.ac.ir

#### Recruitment status

**Recruitment complete**

#### Funding source

#### Expected recruitment start date

2023-04-22, 1402/02/02

#### Expected recruitment end date

2023-10-21, 1402/07/29

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Investigating the effect of modified specific carbohydrate diet on disease severity, fecal calprotectin level and disability caused by the disease in people with ulcerative colitis.

**Public title**

LJCarbohydrate-restricted diet in inflammatory bowel disease

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Age above 20 and less than 60 years Patients with mild to moderate ulcerative colitis Willingness to participate in the study

**Exclusion criteria:**

Changing the type of medicine used and its dosage during the last month Having other intestinal diseases (malignancies, infectious diseases) Suffering from other inflammatory diseases and kidney diseases and diabetes Pregnancy or breastfeeding Use of antibiotics, or use of pre- or probiotic products, or use of multivitamin and mineral supplements, or use of anti-inflammatory supplements such as w3 and curcumin during the intervention and in the one-month period before the intervention. Smoking and drug use History of hospitalization during the last three months

**Age**

From **20 years** old to **60 years** old

**Gender**

Both

**Phase**

N/A

**Groups that have been masked***No information***Sample size**Target sample size: **42****Randomization (investigator's opinion)**

Randomized

**Randomization description**

Before starting the intervention, people will be placed in double blocks in terms of gender (male/female) and drug category. Random allocation of people placed in each block to intervention and non-intervention groups will be done. In order to randomly assign people to groups, each person is assigned a code and these codes are poured into a container. A person outside the study is then asked to draw codes from the container using a lottery. The first code will be assigned to the intervention group, the second code will be assigned to the control group, and the rest of the people will be randomly assigned to two groups.

**Blinding (investigator's opinion)**

Not blinded

**Blinding description****Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Faculty of Medicine - Tehran University of Medical Sciences (Research Ethics Committee)

**Street address**

Faculty of Nutrition Sciences and Dietetics, Hojat Dost Alley, Khanaderi, Keshavarz Blvd., Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

1417653761

**Approval date**

2023-02-11, 1401/11/22

**Ethics committee reference number**

IR.TUMS.MEDICINE.REC.1401.753

**Health conditions studied****1****Description of health condition studied**

Inflammatory bowel disease (ulcerative colitis)

**ICD-10 code**

K51

**ICD-10 code description**

Ulcerative colitis

**Primary outcomes****1****Description**

Illness severity

**Timepoint**

Before the intervention and 6 weeks later

**Method of measurement**

9-point partial Mayo score questionnaire

**2****Description**

Fecal calprotectin levels

**Timepoint**

Before the intervention and 6 weeks later

**Method of measurement**

Eliza kit

### **3**

#### **Description**

Disability due to illness

#### **Timepoint**

Before the intervention and 6 weeks later

#### **Method of measurement**

questionnaire

### **Secondary outcomes**

empty

### **Intervention groups**

#### **1**

##### **Description**

Intervention group: People in the intervention group will receive a modified specific carbohydrate diet and essential tips during the diet to follow for 6 weeks. Before the start of the main intervention, all the selected people enter the Run-in period for two weeks, to collect complete information about the patients' food intake. During this period, 2 24-hour food reminders including two working days and one day off per week are completed. The physical activity of the patients will be recorded through the IPAQ questionnaire. All people will be asked not to change their physical activity and medication during the study compared to before the study and to avoid smoking during the study. The severity of the disease, fecal calprotectin level and disability caused by the disease will be evaluated at the beginning and end of the study. Important points during the prescribed modified specific carbohydrate diet: 1- The consumption of any kind of bread prepared from wheat flour during this period is prohibited. 2- The use of wheat flour in the preparation of daily meals is prohibited. 3- It is forbidden to use any kind of cake, cookies, biscuits, etc. made from wheat flour. 4- It is forbidden to consume any kind of milk and products containing milk. 5- It is forbidden to consume all kinds of cheese except old cheeses that have small amounts of lactose. 6- It is forbidden to consume all types of yogurt, except the leftover and old yogurts that contain small amounts of lactose. 7- In the cereal group, the use of oats, rice and quinoa is free. 8- There are no restrictions on the type of oils. 9- The consumption of food with preservatives is prohibited. 10- The consumption of all kinds of meats is free, except processed meats such as sausages, sausages, etc. 11. The consumption of artificial sweeteners and foods that have been prepared with these sweeteners is prohibited.

##### **Category**

Treatment - Other

#### **2**

##### **Description**

Control group: People in the control group will follow their usual diet along with the nutritional recommendations

related to their disease during these 6 weeks. Before the start of the main intervention, all the selected people enter the Run-in period for two weeks, to collect complete information about the patients' food intake. During this period, 2 24-hour food reminders including two working days and one day off per week are completed. The physical activity of the patients will be recorded through the IPAQ questionnaire. All people will be asked not to change their physical activity and medication during the study compared to before the study and to avoid smoking during the study. The severity of the disease, fecal calprotectin level and disability caused by the disease will be evaluated at the beginning and end of the study.

##### **Category**

Other

### **Recruitment centers**

#### **1**

##### **Recruitment center**

###### **Name of recruitment center**

Shariati Hospital

###### **Full name of responsible person**

Mohammadreza Saboori

###### **Street address**

Shariati Hospital, Jalal Al Ahmad Street, North Kargar Street, Tehran

###### **City**

Tehran

###### **Province**

Tehran

###### **Postal code**

1411711335

###### **Phone**

+98 21 84901

###### **Email**

shariatihosp@tums.ac.ir

### **Sponsors / Funding sources**

#### **1**

##### **Sponsor**

###### **Name of organization / entity**

Tehran University of Medical Sciences

###### **Full name of responsible person**

Dr. Akbar Fatuhi (research assistant, Tehran University of Medical Sciences)

###### **Street address**

Keshavarz Blvd

###### **City**

Tehran

###### **Province**

Tehran

###### **Postal code**

1417653911

###### **Phone**

+98 21 8163 3698

###### **Email**

vcr@tums.ac.ir

**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**  
Tehran University of Medical Sciences  
**Proportion provided by this source**

100

**Public or private sector**  
Public

**Domestic or foreign origin**  
Domestic

**Category of foreign source of funding**  
*empty*

**Country of origin**

**Type of organization providing the funding**  
Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**  
Tehran University of Medical Sciences

**Full name of responsible person**  
Mohammadreza Saboori

**Position**  
Masters student

**Latest degree**  
Bachelor

**Other areas of specialty/work**  
Nutrition

**Street address**  
Unit 1, No. 9, Kouchetan 1st Street, Pasdaran, Tehran

**City**  
Tehran

**Province**  
Tehran

**Postal code**  
1958844153

**Phone**  
+98 21 2665 2428

**Email**  
Mohammadreza.saboori96@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Tehran University of Medical Sciences

**Full name of responsible person**  
Hossien Imani

**Position**  
Assistant professor

**Latest degree**  
Ph.D.

**Other areas of specialty/work**  
Nutrition

**Street address**  
No. 44, Shahid Hojjat Doost Alley, Naderi St,

Keshavarz Boulevard

**City**  
Tehran

**Province**  
Tehran

**Postal code**  
1416643931

**Phone**  
0098 21 889900285

**Email**  
h\_imani@sina.tums.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Tehran University of Medical Sciences

**Full name of responsible person**  
Mohammadreza Saboori

**Position**  
Masters student

**Latest degree**  
Bachelor

**Other areas of specialty/work**  
Nutrition

**Street address**  
Unit 1, No. 9, Kouchetan 1st Street, Pasdaran, Tehran

**City**  
Tehran

**Province**  
Tehran

**Postal code**  
1958844153

**Phone**  
+98 21 2665 2428

**Email**  
Mohammadreza.saboori96@gmail.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available